(Q35975656)

11 August 2017

1 reference

title

Role of Toll-like receptors in antisense and siRNA [corrected]. (English)

1 reference

11 August 2017

0 references

Sudhir Agrawal

1

1 reference

11 August 2017

Ekambar R Kandimalla

series ordinal

2

1 reference

11 August 2017

language of work or name

1 reference

1 December 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

22

1 reference

11 August 2017

issue

12

1 reference

11 August 2017

page(s)

1533-1537

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1042

11 August 2017

exact match

0 references

cites work

Antisense therapeutics: is it as simple as complementary base recognition?

1 reference

A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

21 January 2018

1 reference

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

21 January 2018

1 reference

Respirable antisense oligonucleotides: a new drug class for respiratory disease

21 January 2018

1 reference

Antisense therapy in oncology: new hope for an old idea?

21 January 2018

1 reference

Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus

21 January 2018

1 reference

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

21 January 2018

1 reference

Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors

21 January 2018

1 reference

Role of Toll-like receptors in pathogen recognition.

21 January 2018

1 reference

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

21 January 2018

1 reference

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

21 January 2018

1 reference

Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3.

21 January 2018

1 reference

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity

21 January 2018

1 reference

'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents

21 January 2018

1 reference

Immunotherapeutic uses of CpG oligodeoxynucleotides

21 January 2018

1 reference

Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3.

21 January 2018

1 reference

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

21 January 2018

1 reference

Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.

21 January 2018

1 reference

Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.

21 January 2018

1 reference

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies

21 January 2018

1 reference

Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.

21 January 2018

1 reference

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

21 January 2018

1 reference

siRNAs: applications in functional genomics and potential as therapeutics

21 January 2018

1 reference

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells

21 January 2018

1 reference

Expression profiling reveals off-target gene regulation by RNAi

21 January 2018

1 reference

Activation of the interferon system by short-interfering RNAs

21 January 2018

1 reference

In vivo activity of nuclease-resistant siRNAs

21 January 2018

1 reference

Biodistribution of phosphodiester and phosphorothioate siRNA.

21 January 2018

1 reference

Challenges for RNAi in vivo

21 January 2018

1 reference

CpG DNA and LPS induce distinct patterns of activation in human monocytes

21 January 2018

1 reference

Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment.

21 January 2018

1 reference

Interferon-alpha/beta receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006

21 January 2018

1 reference

Induction of an interferon response by RNAi vectors in mammalian cells

21 January 2018

1 reference

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

21 January 2018

1 reference

7 January 2021

Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus

1 reference

7 January 2021

Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects

1 reference

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

7 January 2021

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

7 January 2021

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

1 reference

7 January 2021

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

1 reference

7 January 2021

Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenti

1 reference

7 January 2021

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

1 reference

7 January 2021

Network interactions in inspiratory (I) and expiratory (E) neuron populations as indicated by high-frequency oscillations.

1 reference

7 January 2021

Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells

1 reference

7 January 2021

Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion

1 reference

7 January 2021

Was induction of HIV-1 through TLR9?

1 reference

7 January 2021

Effect of different chemically modified oligodeoxynucleotides on immune stimulation

1 reference

7 January 2021

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection

1 reference

7 January 2021

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

7 January 2021

Antisense therapeutics

1 reference

7 January 2021

Genta sued over NDA withdrawal

1 reference

7 January 2021

In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats

1 reference

7 January 2021

Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects

1 reference

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT1042

1 reference

release_d4eamdgz3vhwbfnsvhapuv4m24

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d4eamdgz3vhwbfnsvhapuv4m24

24 November 2022

mapped directly with Wikidata item

1 reference